Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-02-01
2005-02-01
Weber, Jon P. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C530S331000
Reexamination Certificate
active
06849605
ABSTRACT:
A novel method of treating and preventing viral infection is provided. In particular a method of blocking viral infection facilitated by a serine proteolytic (SP) activity is disclosed, which consists of administering to a subject suffering or about to suffer from viral infection a therapeutically effective amount of a compound having a serine protease inhibitory or serpin activity. Among compounds are α1-antitrypsin (AAT), peptide derivatives from the carboxyterminal end of AAT, and man-made, synthetic compounds mimicking the action of such compounds. The preferred viral infections include retroviral infection such as human immunodeficiency virus (HIV) infection.
REFERENCES:
patent: 4818538 (1989-04-01), Rideout et al.
patent: WO9407525 (1994-04-01), None
patent: WO9709346 (1997-03-01), None
patent: WO9709347 (1997-03-01), None
patent: WO9710222 (1997-03-01), None
patent: WO9806417 (1998-02-01), None
patent: WO9849190 (1998-11-01), None
patent: WO9943308 (1999-09-01), None
patent: WO0052034 (2000-09-01), None
Geiben-Lynn Ralf (J Biol Chem 277 (44) 42352-57, 2002).*
Shapiro, Leland (FASEB Journal 15(1), 115-122, 2001).*
Turpin J. A. (Antiviral Research 29 (2-3) 269-77, 1996).*
McNeely (Blood 90, 1141, 1997).*
Vollenweider F (Biochemical Journal 314 ( Pt 2) 521-32, 1996).*
Anderson (J. Biol. Chem. 268, 24887, 1996).*
Adelman S.F. et al., “Protease inhibitors suppress fibrinolytic activity of herpes virus-transformed cells”,J Gen Virol,1982, 60(Pt I):15-24.
Altieri, D.C.J Leukoc Biol 1995, 58,120-127.
Aoki H, Akaike T, Abe K, Kuroda M, Arai S, Okamura R, Negi A, Maeda H.Antiviral effect of oryzacystatin, a proteinase inhibitor in rice, against herpes simplex virus type I in vitro and in vivo.Antimicrob Agents Chemother Apr. 1995;39(4):846-9.
Beal, M.F., “Mitochondria, Free Radicals, and Neurodegeneration”,Curr. Opin. Neurobiol.,1996, 6, 661-666.
Beck, K.F. et al. inJ Exp Biol 1999,202, 645-653.
Bjorck L, Grubb A, Kjellen L. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J Virol Feb 1990;64(2):941-3.
Bratt J, Palmblad J.Cytokine-induced neutrophil1 5 mediated injury of human endothelial cells. J ImmunolJul. 15, 1997; 159(2):812-8.
Chesnokova NB, Maichuk YF.Antiproteases in herpetic keratitis.Metab Pediatr Syst Ophthalmol 1986;9(1):593-6.
Cilberto et al., 1995,Cell,41:531-540.
Deigner, H.P. and R. Kinscherf, “Modulating Apoptosis: Current Applications and Prospects for Future Drug Development”, Curr MedChem1999, 6, 399-414.
Dery, O. and Bunnett,N. W. Biochem Soc Trans 1999,2 7,246-254.
Dery, O. et al.Am J Physiol 1998,2 74, C 1429 -C 1452.
DiIanni CL, Drier DA, Deckman IC, McCann PJ 3d, Liu F, Roizinan B, Colonno RJ, Cordingley MG. Identification of the herpes simplex virus-I protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products. Biol Chem Jan. 25, 1993;268(3):2048-51.
Dilanni CL, Stevens JT, Bolgar M, O'Boyle DR 2nd, Weinheimer SP, Colonno RJ. Identification of the serine residue at the active site of the herpes simplex virus type 1 protease. J Biol Chem Apr. 29, 1994;269(17):12672-6.
Ding, A. et al., in J.Immunol.1990, 145, 940.
Estaquier J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen JC. Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists. Blood Jun. 15, 1996;87(12):4959-66.
Flaitz CM, Hicks MJ. “Molecular piracy: the viral link to carcinogenesis.”Oral OncolNov. 1998;34(6):448-53.
Goureau, O. et al., inProc. Natl. Acad. Sci. U.S.A.1993, 90, 4276.
Griffin, William C. , “Calculation of HLB Values of Non-Ionic Sufactants”, [H. L. B.—The Hydrophilic-Lipoophilic Balance], J. Soc. Cos. Met. Chem., vol. 5, p. 249 (1954).
Heck, D. E. et al., inJ. Biol. Chem.1990, 267, 21277.
Holwerda BC. Herpesvirus proteases: targets for novel antiviral drugs. Antiviral Res Jun. 1997;35(1):1-21.
Jabs, Thorsten, “Reactive Oxygen Intermediates as Mediators of Programmed Cell Death in Plants and Animals”,Biochem Pharmacol1999 57, 231-245.
Kaufmann, Scott H., Serge Desnoyers, Yvonne Ottaviano, Nancy E. Davidson, and Guy G. Poirier, “Specific Proteolytic Cleavage of Poly(ADP-ribose) Polymerase: An Early Marker of Chemotherapy-induced Apoptosis”,Cancer Res1993, 53, 3976.
Kidd, Vincent .J., Proteolytic Activities That Mediate Apoptosis,Annu Rev Physiol,1998, 60, 533.
Kido H, Niwa Y, Beppu Y, Towatari T.Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus. Adv Enzyme Regul1996;36:325-47.
Kirkeboen, K.A. and Strand, O.A. inActa Anaesthesiol Scand 1999, 43,275.
Langer, R.Nature1998, 392, 5.
Lomas DA, Elliott PR, Carrell RW.Commercial plasma alphal-antitrypsin(Prolastin)contains a confornationally inactive, latent component.Eur Respir J Mar. 1997;10(3):672-5.
Lowenstein, C. J. and Snyder, S.H. inCell1992, 70, 705-707.
Lowenstein C. J. et al.in Proc. Natl. Acad. Sci. USA,1993, 90, 9730.
McCall, T.B. et al., inBiochem. Biophys. Res. Commun.1992,186, 680.
Meki AR, Mohey El-Dean ZM.Serum interleukin-lbeta, interleukin-6, nitric oxide and alphal-antitrypsin in scorpion envenomed children.Toxicon Dec. 1998;36(12):1851-9.
Molle W. et al. inJ Immunol1997, 159, 3555.
Morel, J. B. and Dangle, J.L.,Cell Death Differ1997, 4, 67 1; Beal, M. F.,Curr Opin Neurobiol1996, 6, 661.
Nathan, C. inFASEB J.1992, 6, 3051.
Ooka T, Hatano Y, Yamamoto M, Ogawa K, Saika S.Protective effects of human urinary trypsin inhibitor against trypsin-induced relaxation in rat aorta. Crit Care MedNov. 1996;24(11):1903-7.
Patel R.P., et al. inBiochim Biophys Acta1999,1411,385-400.
Patel T, Gores GF, Kaufmann SH.The role of proteases during apoptosis. FASEB JApr. 1996;10(5):587-97.
Premack, B. A. and Schall, T. J., “Chemokine Receptors: Gateways to Inflammation and Infection”,Nature Medicine, 2, 1174-1178 (1996).
Pryor WA, Dooley MM, Church DF.Mechanisms of cigarette smoke toxicity: the inactivation of human alpha-l-proteinase inhibitor by nitric oxide/isoprene mixtures in air.Chem Biol Interact Jul. 1985;54(2):171-83.
Punjabi, C. J. et al., inJ. Immunol.1992, 149, 2179.
Rehman A, Whiteman M, Halliwell B.Scavenging of hydroxyl radicals but not of peroxynitrite by inhibitors and substrates of nitric oxide syntheses.Br J Pharmacol Dec. 1997; 122(8):1702-6.
Schini et al. inCirc Res1994, 74, 24.
Sharpstone D, Rowbottom A, Nelson M, Gazzard B.Faecal alpha I antitrypsin as a marker of gastrointestinal disease in HIV antibody positive individuals.Gut Feb. 1996;38(2):206-10.
Shimizu T, Pommier Y.DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies.Exp Cell Res Aug. 1, 1996;226(2):292-301.
Smith, M. E. inNeurochem Res1999, 24, 261.
Wood, E.R. et al. inBiochem Biophys Res Commun1993,191, 767-74.
Katten Muchin Zavis & Rosenman
Lukton David
Sira Serge
The Trustees of University Technology Corporation
Villacorta Gilberto M.
LandOfFree
Inhibitors of serine protease activity, methods and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of serine protease activity, methods and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of serine protease activity, methods and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3464920